A Phase III Study Including a Single-Arm, Open-Label, Multi-Dose PK Study Cohort and a Randomized, Evaluator-Masked, Active Drug Controlled, Parallel Group, Multicenter, Bridging Study Cohort With a Long-term Follow-up Phase Assessing the Efficacy and Safety of DE-117B Eye Drops in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.
Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any.
The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.
It will investigate the safety of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.
There will be a bridging cohort and extension follow-up phase

开始日期2024-11-01

申办/合作机构

Santen Pharmaceutical Co., Ltd.

NCT05279716

/ Unknown status临床4期

Safety and Efficacy Study in NTG, POAG, Glaucoma Suspect, Ocular Hypertension Patients With Diagnosed Prostaglandin Associated Peri-orbitopathy Switching From Preserved Prostaglandin Analogues Monotherapy to Omidenepag Isopropyl

This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.
the investigators would like to confirm the real world evidence(RWE) of safety and efficacy after changing to Eybelis ophthalmic solution 0.002%.

开始日期2022-02-15

申办/合作机构

Santen Pharmaceutical Asia Pte Ltd.

100 项与 Omidenepag Isopropyl 相关的临床结果

登录后查看更多信息

100 项与 Omidenepag Isopropyl 相关的转化医学

登录后查看更多信息

100 项与 Omidenepag Isopropyl 相关的专利（医药）

登录后查看更多信息

项与 Omidenepag Isopropyl 相关的文献（医药）

2024-12-01·REPRODUCTIVE TOXICOLOGY

Male premating treatment in FEED studies: Length is not everything

Review

作者: Barrow, Paul

The ICH S5(R3) guideline recommends that male rodents in a FEED study are treated for ≥2 weeks before mating, which has frequently been criticized as being too short for the detection of all effects on sperm maturation, mating behavior and male fertility. In a FEED study, males generally continue for ≥5 weeks after the start of cohabitation. This review determines how often a 2-week premating treatment period for males was used in FEED studies of novel drugs approved by the FDA in 2022 and 2023. The male premating treatment duration was specified for 44 drugs. Only 16 % of these had a 2-week male premating treatment period. 52 % of drugs had a 4-week period. No examples were found in the literature of drugs for which male-mediated reproductive toxicity could have been detected using a 4-week, but not a 2-week, premating treatment period. Repeat dose studies in 2 species, with a duration of treatment at least equivalent to that in patients, are generally completed before the FEED study is planned. Providing no effects on male reproductive organs are detected in the repeat dose studies, a 2-week premating treatment period appears sufficient for the detection of effects on male mating performance. If toxic effects on spermatogenesis are detected in the repeat dose studies, a male FEED study serves little regulatory purpose. Even in the absence of effects on mating performance and fertility in the FEED study, a drug-related disruption of spermatogenesis would likely be considered pertinent to the human.

2024-11-08·Translational Vision Science & Technology

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Article

作者: Mano, Hidetoshi ; Fuwa, Masahiro ; Odani-Kawabata, Noriko ; Iwamura, Ryo ; Yamamura, Kenzo

Purpose:

To evaluate the ocular distribution of omidenepag isopropyl (OMDI) and its active form omidenepag (OMD), an EP2 receptor agonist, after topical administration of OMDI into rabbit and monkey eyes, and to determine whether OMDI and OMD interact with target receptors or enzymes of other antiglaucoma agents.

Methods:

Both eyes of six rabbits and of 14 monkeys were topically instilled with 0.03% [14C]-OMDI. Rabbits were sacrificed after one to four hours, and ocular tissues were collected. Monkeys were sacrificed after 0.25 to 24 hours, and blood and ocular tissues were collected. Radioactivity was measured in each sample. The interactions of OMDI and OMD with the receptors and enzymes associated with the mechanisms of action of other antiglaucoma agents were evaluated.

Results:

Most radioactivity applied to rabbit eyes was recovered as OMD from the cornea, aqueous humor, and iris-ciliary body. Similarly, high concentrations of radioactivity were observed in monkey cornea, bulbar/palpebral conjunctiva, and trabecular meshwork. OMD bound to EP2 receptors, but neither OMD nor OMDI bound to α2A, β1, and β2 adrenergic receptors or inhibited enzymatic activities of CA1 and CA2. OMD and OMDI had little or no effect on ROCK1 and ROCK2.

Conclusions:

OMDI rapidly permeates rabbit and monkey corneas and is converted to OMD, which distributes into anterior ocular tissues. Neither OMD nor OMDI interacted with the target receptors or enzymes of other antiglaucoma agents, suggesting that OMD interacts highly selectively with EP2 receptors.

Translational Relevance:

OMDI is a specific antiglaucoma agent that interacts selectively with ocular EP2 receptors.

2024-08-01·NEUROSCIENCE

Neuroprotective effect of omidenepag on excitotoxic retinal ganglion cell death regulating COX-2–EP2–cAMP–PKA/Epac pathway via Neuron–Glia interaction

Article

作者: Honjo, Megumi ; Aihara, Makoto ; Sakata, Rei ; Nakamura, Natsuko ; Yamagishi-Kimura, Reiko ; Watanabe, Sumiko

Glutamate excitotoxicity is involved in retinal ganglion cell (RGC) death in various retinal degenerative diseases, including ischemia-reperfusion injury and glaucoma. Excitotoxic RGC death is caused by both direct damage to RGCs and indirect damage through neuroinflammation of retinal glial cells. Omidenepag (OMD), a novel E prostanoid receptor 2 (EP2) agonist, is a recently approved intraocular pressure-lowering drug. The second messenger of EP2 is cyclic adenosine monophosphate (cAMP), which activates protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). In this study, we investigated the neuroprotective effects of OMD on excitotoxic RGC death by focusing on differences in cAMP downstream signaling from the perspective of glia-neuron interactions. We established a glutamate excitotoxicity model in vitro and NMDA intravitreal injection model in vivo. In vitro, rat primary RGCs were used in an RGC survival rate assay. MG5 cells (mouse microglial cell line) and A1 cells (astrocyte cell line) were used for immunocytochemistry and Western blotting to evaluate the expressions of COX-1/2, PKA, Epac1/2, pCREB, cleaved caspase-3, inflammatory cytokines, and neurotrophic factors. Mouse retinal specimens underwent hematoxylin and eosin staining, flat-mounted retina examination, and immunohistochemistry. OMD significantly suppressed excitotoxic RGC death, cleaved caspase-3 expression, and activated glia both in vitro and in vivo. Moreover, it inhibited Epac1 and inflammatory cytokine expression and promoted COX-2, pCREB, and neurotrophic factor expression. OMD may have neuroprotective effects through inhibition of the Epac pathway and promotion of the COX-2-EP2-cAMP-PKA pathway by modulating glia-neuron interaction.

项与 Omidenepag Isopropyl 相关的新闻（医药）

2024-08-18

·SYNAPSE

Visiox Pharmaceuticals announces merger with Ocuvex Therpeutics

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals. Visiox Pharmaceuticals Inc announced it has entered into a definitive merger agreement with Ocuvex Therapeutics Inc. According to a news release, Ocuvex, a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders, has a pipeline of near-term ophthalmic medicines. The companies noted the strategic combination will position the newly combined entity as a potential leader in the eye care sector with a portfolio of ophthalmic medicines. Visiox's products include omidenepag isopropyl ophthalmic solution (Omlonti), licensed by Visiox from Santen Pharmaceuticals a year ago. Another, PDP-716 (brimonidine) 0.35%, is the next closest to the market. It is a once-daily solution that the company has been hoping to launch in early 2025. It also has SDN-037 (difluprednate) 0.04%, which will grow Ocuvex's market presence and accelerate the commercialization of these therapeutics. Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals. "The combination of Visiox and Ocuvex makes for a perfect match," Ryan S. Bleeks, CEO of Visiox, said in the news release. "We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care."

并购上市批准

2023-07-18

·BioSpace

Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America

OSAKA, Japan--(BUSINESS WIRE)-- Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox Pharmaceuticals, Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI®, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®. Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI®. Santen has also made an asset transfer agreement with Harrow Health, Inc. (Nasdaq: HROW, hereafter Harrow Health) for Flarex® (an eyedrop for ocular surface Inflammation associated with dry eye), Natacyn® (an eyedrop for fungal blepharitis, conjunctivitis, and keratitis), TobraDex® ST (an eyedrop for ocular inflammation with presence of risk of infection), ZERVIATE® (an eyedrop for ocular itch associated with allergic conjunctivitis), FRESHKOTE® (an eyedrop for temporary relief of symptoms of dry eye) and an out-licensing agreement on the rights for product manufacturing, commercialization, and sales of Verkazia® (an eyedrop for vernal keratoconjunctivitis) and Cationorm® Plus (an artificial tear). Under the terms of the agreement, Santen will sell and transfer Flarex®, Natacyn®, TobraDex® ST, ZERVIATE®, and FRESHKOTE® and grant Harrow Health exclusive rights in the U.S. and Canada for product manufacturing and commercialization of Verkazia®, and exclusive rights in Canada for product manufacturing and commercialization of Cationorm® Plus. Santen will receive an upfront payment for the asset transfer and the out-licensing and is eligible for royalties on net sales of Verkazia® and Cationorm® Plus. Santen will continue to strive to improve profitability from a company-wide perspective, secure investment in research and development that serves unmet medical needs, and further promote the development of a promising pipeline to maximize its contribution to patients. About Santen As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in more than 60 countries and regions. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website ( ). View source version on businesswire.com: Contacts Corporate Communications Santen Pharmaceutical Co., Ltd. E-mail: communication@santen.com Source: Santen Pharmaceutical Co., Ltd. View this news release online at:

引进/卖出

2023-02-07

·药时代

2022年FDA批准的15个小分子：临床用途及其合成

前言本文列举了2022年批准用于临床的小分子药物，按照批准日期的时间顺序列出。值得关注的是，获批的分子中有4个包含磺胺官能团，1个是大环，2个是甾体结构。两种放射性同位素/造影剂和一种含氘药物获得批准。后者代表了未来药物发现工作的一个创新的起点。卤素（主要是氯化和氟化）药物在获批药物中的比例仍然保持一致，这凸显了卤素在药物发现中的重要性。除了两种具有类固醇结构的药物外，所有结构都至少含有一个芳环。01Daridorexantdaridorexant（商品名Quviviq®）于2022年1月7日获得批准并由 Idorsia US 推出，是一种 1,2,3-三唑衍生物，预计到 2026 年全球销售额为 10.52 亿美元。据推测，其治疗失眠的作用机制是通过拮抗食欲素受体。食欲素神经肽信号系统在清醒中发挥作用。合成路线如下，可进行千克规模制备。02Abrocitinibabrocitinib（商品名 Cibinqo®）于2022年1月14日获得批准，是一种选择性 JAK1抑制剂，可有效且安全地治疗特应性皮炎(AD)，具有良好的口服生物利用度以及缺乏免疫原性，解决目前可用的生物药物的一些局限性。预计2026年全球销售额预测为7.6亿美元。Abrocitinib 由辉瑞公司开发，用于治疗中度至重度AD患者。合成路线如下：03Mitapivatmitapivat（商品名Pyrukynd®）于2022年2月17日获得批准，由Agios Pharmaceuticals 开发，被批准用于治疗遗传性溶血性贫血。预计2026年全球销售额预测为5.11亿美元。该分子是丙酮酸激酶的变构激活剂，分子中包含磺酰胺。合成路线如下：04呼吸道传染的病毒最危险Pacritinib（商品名 Vonjo®）于2022 年2月28日获准用于治疗血小板减少的成人高危原发性或继发性骨髓纤维化。由 S*BIO Pte Ltd.（新加坡）发现并合成，它是一种JAK2抑制剂，预计 2026年的销售额为 4.96 亿美元。合成路线如下：05GanaxoloneGanaxolone（商品名 Ztalmy®）于2022年3月18日获得批准，用于治疗细胞周期蛋白依赖性激酶样5（CDKL5）缺陷症的癫痫发作。Ganaxolone 的作用机制尚不清楚。很可能它调节（正变构调节剂）突触和突触外 GABAA 受体以使过度兴奋的神经元正常化。预计2026年全球销售额预测为4.34亿美元。合成路线如下：06Lutetium (177Lu) Vipivotide TetraxetanLutetium(177Lu) vipivotide tetraxetan（商品名 Pluvicto®）是一种基于尿素的前列腺特异性膜抗原 (PSMA) 抑制剂。预计2026年全球销售额预测为8.51亿美元。作用机制源于Lutetium 177，它向表达PSMA的细胞传递其β负发射。它由Advanced Accelerator Applications 开发，已于2022年3月23日获批用于治疗其他疗法失败的前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌。其结构由 PSMA-617 组成，PSMA-617是一种人类前列腺特异性膜抗原 (PSMA) 靶向配体，与发射β的放射性同位素Lu 177结合。合成路线如下：07Oteseconazole抗真菌药物oteseconazole（商品名 Vivjoa®）于2022年4月26日获得批准，用于降低有外阴阴道念珠菌病病史且无生殖潜力的女性的复发发病率。它由 Mycovia Pharmaceuticals推出，是一种基于四唑的化合物，可抑制CYP51酶，从而导致真菌破坏。合成路线如下：08MavacamtenMavacamten（商品名Camzyos®）于2022年4月28日获批用于治疗某些类别的梗阻性肥厚性心肌病。它是由MyoKardia开发的一种口服活性心肌肌球蛋白抑制剂。预计2028年全球销售额预测为16.58亿美元。合成路线如下：09Vonoprazan (in Combination with Amoxicillin, and Clarithromycin)Vonoprazam（与阿莫西林和克拉霉素联用，商品名Voquezna®）于2022年5月3日获批用于治疗幽门螺杆菌感染。预计2028年全球销售额预测为8.69亿美元。它由Takeda推出，是一种口服生物可利用的钾竞争性酸阻滞剂 (P-CAB)。P-CAB 通过与管腔表面的 K+ 竞争可逆地抑制胃酸分泌，从而阻止胃酸分泌。胃分泌的抑制与阿莫西林和克拉霉素的抗菌活性相结合，使Voquezna® 成为具有协同活性的“组合”。合成路线如下：10TapinarofTapinarof（商品名Vtama®）于2022年5月23日获批用于治疗斑块状银屑病。它是一种芳烃受体 (AhR) 激动剂，由 Dermavant Sciences Inc.开发。它是一种天然衍生的小分子，由昆虫病原线虫的细菌共生体产生。合成路线如下：11DeucravacitinibDeucravacitinib（商品名 Sotyktu®）于2022年9月9日获批，与tapinarof一样用于治疗斑块状银屑病。预计2026年全球销售额预测为11.2亿美元。它是由Bristol Meyers Squibb推出的一种氘化药物，它选择性地靶向TYK2。作者说，氘的引入提高了代谢稳定性。代谢稳定性是一个需要考虑的重要参数，新型基于氘的药物可能会在未来几年出现。此外，C-D键比C-H键更短且有时更具抵抗力。合成路线如下：12GadopiclenolGadopiclenol（商品名 Elucirem®）于2022年9月21日获得批准，与磁共振成像一起用于检测和可视化中枢神经系统和身体血管分布异常的病变。Gadopiclenol是一种大环钆基造影剂 (GBCA)，具有高弛豫特性，旨在通过磁共振成像提高病变检测和表征。它由Bracco推出，其合成来源于外消旋谷氨酸。合成路线如下：13Oomidenepag IsopropylOomidenepag isopropyl（商品名Omlonti®）于2022年9月22日获批，用于降低开角型青光眼或高眼压症患者升高的眼内压。预计2026年全球销售额预测为1.21亿美元。它是一种具有非前列腺素结构的选择性前列腺素E2受体激动剂，由Ube Industries 和 Santen Pharmaceutical 开发。Oomidenepag isopropyl是一种前体药物，可在体内转化为活性形式oomidenepag。合成路线如下：14Taurursodiol (in Combination with Sodium Phenylbutyrate)Taurursodiol（商品名 Relyvrio®）于2022年9月29日批准与苯基丁酸钠联合治疗肌萎缩侧索硬化症 (ALS)，Taurursodiol是一种牛磺胆汁酸结合物。预计2026年全球销售额预测为10.95亿美元。组合产品 Relyvrio® 被认为具有协同作用，可以通过同时抑制内质网和线粒体应激来减少神经元死亡。Taurursodiol可从熊去氧胆酸 (118) 中获得。后者天然存在于熊的肝脏和相关食肉动物中。15futibatinibfutibatinib（商品名 Lytgobi®）于 2022年9月30日获批用于治疗携带FGFR2 基因融合或其他重排的肝内胆管癌，futibatinib是一种高度选择性的不可逆成纤维细胞生长因子受体FGFR1-4 抑制剂。合成路线如下：磺胺类药物反复出现在批准分子中2022 年批准的分子中出现了四种含磺胺类药物。2021年仅有环磺胺类药物odevixibat（商品名Bylvay®）获批用于治疗瘙痒症，而2020年，FDA未批准任何含磺胺类药物。磺胺类化合物通常作为稳定的内酰胺等价物掺入目标分子中。历史上，第一种磺胺类药物是prontosil。这种化合物首先由拜耳化学家 Josef Klarer 和 Fritz Mietzsch 合成，作为旨在寻找可在体内充当抗菌药物的染料的研究计划的一部分。后来，磺胺类药物被广泛用作抗菌剂。另一个著名的探索领域是使用磺胺类药物和电子等排物作为金属酶碳酸酐酶抑制剂。此外，磺胺类药物具有高水解稳定性，这一关键特征有助于设计新型生物活性化合物。结束语本文介绍了 FDA 在2022年批准的所有小分子药物。似乎含磺胺类药物将在 2022 年占据主导地位，有四种分子获批。在发现第一个具有抗菌活性的磺胺类药物多年后，它们的物理化学和药效学特性仍然发挥着重要作用。另一方面，含氘药物 deucravacitinib 代表了药物发现新方法的一个例子，该方法结合了一种不寻常的同位素来提供药物稳定性。用于治疗心肌病的嘧啶二酮 mavacamten 的发现和该分子的巨大预测销售额，强调了在心血管疾病领域寻找新的活性分子的重要性。药物组合，例如vonoprazan（与阿莫西林和克拉霉素联合）和taurursodiol（与苯基丁酸钠联合）仍然是治疗未满足的医学疾病的有效武器。参考文献：Benedetto Tiz, D.; Bagnoli, L.; Rosati, O.; Marini, F.; Santi, C.; Sancineto, L. FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. Pharmaceutics2022, 14, 2538. https://doi-org.libproxy1.nus.edu.sg/10.3390/ pharmaceutics14112538Hunting for Drugs in Chemical Space. Available online: https://cen-acs-org.libproxy1.nus.edu.sg/pharmaceuticals/drug-discovery/Hunting-drugschemical-space/100/i23作者：墨竹封面图来源：123rf推荐阅读患者死亡，在研管线全凉，股价却大涨50%……？卖了8年的PD-1，还能保持20%的增长率，它是怎么做到的？罗氏2022，营收近700亿美元！新增长抵消新冠影响点击这里，报名创新药BD高阶研讨会【上海站】！

申请上市放射疗法上市批准

100 项与 Omidenepag Isopropyl 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10966	-	S01EX06	DB15071

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Santen SAS	2018-09-21
开角型青光眼	日本	Santen Pharmaceutical Co., Ltd.	2018-09-21
高眼压症	日本	Santen SAS	2018-09-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DAISY (Pubmed) 人工标引	临床3期	高眼压症 \| 开角型青光眼	74	Preservative-free Omidenepag Isopropyl (DE-117B) 0.002%	鹹構鹽蓋糧網廠積齋蓋(網夢範鑰膚繭衊鬱鹹廠) = 鬱齋醖顧鏇積醖製壓網鏇願壓鑰積獵淵襯選鑰 (選衊顧夢淵觸構鏇齋獵, 2.05)	相似	2025-01-06
				Omidenepag Isopropyl (OMDI) 0.002% preserved with benzalkonium chloride	鹹構鹽蓋糧網廠積齋蓋(網夢範鑰膚繭衊鬱鹹廠) = 構獵鹹顧蓋憲顧艱網憲鏇願壓鑰積獵淵襯選鑰 (選衊顧夢淵觸構鏇齋獵, 2.01)
NCT02981446 (PEONY, CTgov)	临床3期	开角型青光眼	370	DE-117 (DE-117 Ophthalmic Solution)	醖壓鑰餘齋遞糧糧夢衊(構鹽糧簾壓製簾糧糧鏇) = 積網顧願壓蓋糧餘製窪鏇選廠築鏇選範鑰鏇鹽 (膚範獵繭鹹鹹憲鹹夢鑰, 願醖鏇簾鹽選鹽構糧廠 ~ 遞憲構夢構鹹願獵壓構) 更多	-	2024-03-15
				Latanoprost ophthalmic solution (Latanoprost Ophthalmic Solution 0.005%)	醖壓鑰餘齋遞糧糧夢衊(構鹽糧簾壓製簾糧糧鏇) = 餘製範壓蓋繭構糧網廠鏇選廠築鏇選範鑰鏇鹽 (膚範獵繭鹹鹹憲鹹夢鑰, 繭餘鏇壓齋齋夢顧獵膚 ~ 餘簾構膚繭觸築餘網獵) 更多
APAO2024	N/A	低眼压	-	Omidenepag Isopropyl (OMDI) 0.002%	觸醖鹹夢簾餘夢構築觸(鬱觸鏇鬱築鏇築襯窪衊) = 艱糧醖願膚積膚鬱築膚膚觸積繭壓艱艱獵製鏇 (艱窪網積衊繭壓獵製糧, 3.31)	-	2024-02-22
				Latanoprost	觸醖鹹夢簾餘夢構築觸(鬱觸鏇鬱築鏇築襯窪衊) = 蓋繭餘網齋糧鬱顧憲衊膚觸積繭壓艱艱獵製鏇 (艱窪網積衊繭壓獵製糧, 2.12)
APAO2024	N/A	开角型青光眼	-	Omidenepag Isopropyl 0.002%	獵蓋構觸願淵襯遞餘齋(觸憲餘醖願鹹艱觸範獵) = Anterior chamber depth (ACD) was significantly decreased by 0.05 mm to 0.06 mm 齋築獵糧窪餘襯夢糧艱 (範鹽觸獵築構鏇構遞遞 ) 更多	-	2024-02-22
DAISY (APAO2024)	N/A	开角型青光眼 \| 高眼压症	74	DE-117B (omidenepag isopropyl [OMDI] 0.002% preservative-free formulation)	築襯選築夢窪範鹹顧鑰(築範願衊淵壓蓋築襯夢) = AE rates were similar between DE-117B and OMDI (43.8% vs. 45.9%, respectively) 憲齋蓋憲構壓齋廠鏇壓 (網構範醖齋獵齋觸構襯 ) 更多	积极	2024-02-22
				OMDI 0.002% ophthalmic solution
NCT03697811 (Phase 3, Pubmed \| J Glaucoma)	临床3期	开角型青光眼 \| 高眼压症	107	Omidenepag isopropyl 0.002%	遞夢膚鏇願製簾鬱遞膚(繭壓夢膚壓壓糧鏇製夢) = 鹹壓鬱網網簾鏇鹽觸鏇壓積憲齋遞願衊觸襯壓 (築積範夢淵齋鏇襯艱鹹, 2.12)	积极	2023-12-01
NCT03691649 (CTgov)	临床3期	青光眼	426	DE-117 Ophthalmic Solution (DE-117 Ophthalmic Solution)	膚鹽膚遞醖鹹遞願觸鹽(築鹹廠鹽襯繭壓築襯襯) = 齋壓鬱窪觸鬱鏇淵簾築鏇艱範襯繭遞積願衊遞 (願廠餘鹹醖製襯觸範窪, 艱鏇艱遞願艱築製遞觸 ~ 構簾觸網鬱選願壓網製) 更多	-	2023-08-30
				Timolol Maleate Ophthalmic Solution 0.5% (Timolol Maleate Ophthalmic Solution 0.5%)	膚鹽膚遞醖鹹遞願觸鹽(築鹹廠鹽襯繭壓築襯襯) = 鑰鏇積製鬱製網積餘積鏇艱範襯繭遞積願衊遞 (願廠餘鹹醖製襯觸範窪, 範憲夢觸繭膚簾繭夢範 ~ 積衊製觸廠鏇繭衊糧構) 更多
NCT03697811 (Phase 3, CTgov)	临床3期	开角型青光眼	107	DE-117 Ophthalmic Solution	築糧齋窪製製遞顧製膚(糧壓膚窪淵糧鬱簾蓋繭) = 願廠鹹鏇廠範淵鹹膚製築鹹簾壓鹽襯積選選鹽 (鏇窪壓夢艱顧蓋簾憲襯, 壓壓糧鑰鬱顧遞醖廠鹽 ~ 膚鏇醖憲夢構壓構鑰築) 更多	-	2023-08-30
NCT03691662 (CTgov)	临床3期	青光眼	417	DE-117 Ophthalmic Solution (DE-117 Ophthalmic Solution)	遞憲遞艱構廠築願鑰壓(夢艱網壓願鏇築襯鹹遞) = 鬱獵鏇淵願構簾築醖築範淵壓壓鬱憲觸壓餘繭 (襯壓選構憲構遞築襯糧, 簾壓築製襯築窪膚鏇鬱 ~ 獵築鬱艱遞襯網鑰鬱鏇) 更多	-	2023-08-09
				Timolol Maleate Ophthalmic Solution 0.5% (Timolol Maleate Ophthalmic Solution 0.5%)	遞憲遞艱構廠築願鑰壓(夢艱網壓願鏇築襯鹹遞) = 淵廠顧鑰鹽齋醖願糧築範淵壓壓鬱憲觸壓餘繭 (襯壓選構憲構遞築襯糧, 構製製醖艱衊蓋顧糧鏇 ~ 鹹簾遞衊糧壓簾廠齋餘) 更多
NCT02981446 (PEONY, AAO2021)	临床3期	高眼压症	185	Omidenepag Isopropyl 0.002%	淵範憲襯願網構顧膚築(範齋鑰糧齋蓋憲艱淵蓋) = 餘餘網衊膚衊獵醖範憲淵蓋鏇積衊齋壓衊衊蓋 (廠範製窪窪艱襯壓憲艱, 2.3)	积极	2021-11-14
				Latanoprost 0.005%	淵範憲襯願網構顧膚築(範齋鑰糧齋蓋憲艱淵蓋) = 廠襯壓膚鹹鏇繭構餘蓋淵蓋鏇積衊齋壓衊衊蓋 (廠範製窪窪艱襯壓憲艱, 2.1)